{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:05:35Z","timestamp":1787238335983,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Texas 4000 Distinguished Professorship for Cancer Research"},{"name":"NIH-NCI Cancer Center CORE Support","award":["16672"],"award-info":[{"award-number":["16672"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.diagmicrobio.2019.06.013","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T19:24:32Z","timestamp":1562354672000},"page":"114861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative in vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis"],"prefix":"10.1016","volume":"95","author":[{"given":"Russell E.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7784-7256","authenticated-orcid":false,"given":"Sebastian","family":"Wurster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Beyda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel D.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1128\/JCM.44.2.553-560.2006","article-title":"Rapid susceptibility testing of medically important zygomycetes by XTT assay","volume":"44","author":"Antachopoulos","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0010","doi-asserted-by":"crossref","unstructured":"Arendrup MC, Meletiadis J, Mouton JW et al. 2016. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin Microbiol infect 22:571.e1\u20134.","DOI":"10.1016\/j.cmi.2016.01.017"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/AAC.01364-15","article-title":"Pharmacodynamics of Isavuconazole in a dynamic in vitro model of invasive pulmonary aspergillosis","volume":"60","author":"Box","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0020","unstructured":"Clinical Laboratory Standards Institute. 2017. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. 3rd ed. CLSI standard M38."},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0025","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jac\/dkv380","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0030","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/jac\/dkx263","article-title":"Pharmacokinetics and safety results from the phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2019.06.013_bb0035","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0040","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure\u2013response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0045","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/cid\/cix198","article-title":"Pharmacodynamics of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response","volume":"64","author":"Kovanda","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0050","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/AAC.01354-13","article-title":"Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0055","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1128\/AAC.01355-13","article-title":"Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0060","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.49.3.945-951.2005","article-title":"In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp","volume":"49","author":"Lewis","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0065","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0070","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0075","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/JCM.39.9.3402-3408.2001","article-title":"Colorimetric assay for antifungal susceptibility testing of Aspergillus species","volume":"39","author":"Meletiadis","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0080","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1128\/jcm.30.4.1000-1004.1992","article-title":"Viability of fungal cultures maintained at \u221270 degrees C","volume":"30","author":"Pasarell","year":"1992","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0085","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1469-0691.2008.02024.x","article-title":"Alternaria infections: laboratory diagnosis and relevant clinical features","volume":"14","author":"Pastor","year":"2008","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2019.06.013_bb0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijantimicag.2017.06.009","article-title":"Pathobiology of Lomentospora prolificans: could this species serve as a model of primary antifungal resistance?","volume":"51","author":"Pellon","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0095","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1128\/AAC.02665-15","article-title":"Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis","volume":"60","author":"Petraitis","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0100","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.04907-14","article-title":"Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model","volume":"59","author":"Seyedmousavi","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.06.013_bb0105","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319300033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889319300033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:52:34Z","timestamp":1760003554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889319300033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0732889319300033"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.06.013","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative in vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114861"}}